XR molecular

Combination of Artificial Intelligence and Extended Reality, that provides users with an easier and quicker way to create, visualize, and explore the nuances of molecular structure in one solution by SoftServe R&D.

Watch the video

Identifying a molecular drug target

Researchers must understand
the underlying mechanisms
of the disease as clearly as possible.

Identifying the first lead compound

Find a compound that acts
on the target in the desired way

Lead optimization

Starting with the first lead compound, chemists run tests, and iteratively refine a succession of a structurally related compound until they find the optimal active structure

Pre-clinical safety and efficacy trials

At this stage, investigations primarily focus on safety. Before human candidates are tested, a number of critical pre-clinical hurdles must be overcome

Human clinical trials

Human trials establish safety,
tolerability, dosage, and efficacy

Regulatory approval
and launch

Finally, documentation of experiments and results must be prepared

A typical drug design lifecycle

inevitably goes through several stages:

Start to finish, the process usually lasts
10 to 15 years

 

The cost of a conventional drug

is over $1B

 

and only one drug out
of thousands of candidates
ever reaches the patient

from ideation to final approval and commercial distribution

We have created a solution that challenges legacy paradigms allowing to speed up the delivery of effective results

 

solution

Efficient design and screening of novel compounds
is a major challenge in drug and material design

SoftServe’s extended reality (XR) molecular explorer unites XR and artificial intelligence (AI) to provide users with an easy way to generate a new compound, visualize it, and examine its molecular structure.

01

02

03

04

05

06

07

08